American Heart Journal
Volume 157, Issue 3 , Pages 423-427 , March 2009

The rationale and design of the FORωARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation

  • Alejandro Macchia

      Affiliations

    • Fundación GESICA (Grupo de Estudio en Investigación Clínica en Argentina), Buenos Aires, Argentina
    • Corresponding Author InformationReprint requests: Alejandro Macchia, Fundación GESICA, Av. Rivadavia 2358, 1 “4” – C1034ACP Buenos Aires, Argentina.
    • ,
  • Sergio Varini

      Affiliations

    • Fundación GESICA (Grupo de Estudio en Investigación Clínica en Argentina), Buenos Aires, Argentina
    • ,
  • Hugo Grancelli

      Affiliations

    • Fundación GESICA (Grupo de Estudio en Investigación Clínica en Argentina), Buenos Aires, Argentina
    • ,
  • Daniel Nul

      Affiliations

    • Fundación GESICA (Grupo de Estudio en Investigación Clínica en Argentina), Buenos Aires, Argentina
    • ,
  • Nicolas Laffaye

      Affiliations

    • Fundación GESICA (Grupo de Estudio en Investigación Clínica en Argentina), Buenos Aires, Argentina
    • ,
  • Daniel Ferrante

      Affiliations

    • Fundación GESICA (Grupo de Estudio en Investigación Clínica en Argentina), Buenos Aires, Argentina
    • ,
  • Gianni Tognoni

      Affiliations

    • Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    • ,
  • Hernan C. Doval

      Affiliations

    • Fundación GESICA (Grupo de Estudio en Investigación Clínica en Argentina), Buenos Aires, Argentina
    • ,
  • on behalf of the FORWARD investigators

Received 16 September 2008 ,Accepted 31 October 2008.

References 

  1. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493–498
  2. GESICA Investigators . Randomised trial of telephone intervention in chronic heart failure: DIAL trial. BMJ. 2005;331:425
  3. GISSI-Hf Investigators . Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;
  4. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447–455
  5. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789–1794
  6. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833
  7. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690–1696
  8. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840
  9. Opolski G, Torbicki A, Kosior D, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest. 2004;126:476–486
  10. Bialy D, Lehmann MH, Schumacher DN, et al. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol. 1992;19:41A
  11. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952
  12. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet. 1987;1:526–529
  13. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561–1564
  14. Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380–1384
  15. Wolf P, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke and medical costs. Arch Intern Med. 1998;158:229–234
  16. de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation a meta-analysis. Arch Intern Med. 2005;165:258–262
  17. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–1872
  18. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007;356:935–941
  19. Singh BN, Connolly SJ, Crijns HJGM, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–999
  20. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–2687
  21. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:700–752
  22. Jordan H, Matthan N, Chung M, et al. Effects of omega-3 fatty acids on arrhythmogenic mechanisms in animal and isolated organ/cell culture studies. Evidence report/technology assessment No. 92 (Prepared by Tufts-New England Medical Center Evidence-based Practice Center, under Contract No. 290-02-0022). AHRQ Publication No 04-E011-2. Rockville, MD: Agency for Healthcare Research and Quality; 2004;
  23. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205–1209
  24. Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336:1046–1053
  25. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287:1815–1821
  26. Mozaffarian D, Lemaitre RN, Kuller LH, et al. Cardiovascular Health Study. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation. 2003;107:1372–1377
  27. He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation. 2004;109:2705–2711
  28. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447–455
  29. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298–304
  30. Jahangiri A, Leifert WR, Patten GS, et al. Termination of asynchronous contractile activity in rat atrial myocytes by n-3 polyunsaturated fatty acids. Mol Cell Biochem. 2000;206:33–41
  31. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004 27;110:368–373
  32. Calò L, Bianconi L, Colivicchi F, et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45:1723–1728

 ClinicalTrial.gov identifier: NCT00597220.

PII: S0002-8703(08)00975-7

doi: 10.1016/j.ahj.2008.10.027

American Heart Journal
Volume 157, Issue 3 , Pages 423-427 , March 2009

Article Tools

* Image Usage & Resolution